Pfizer, the world's largest drugmaker, is scheduled to repo
rt fourth-quarter results before the opening bell on Wednesday, February 3.
The consensus First Call EPS estimate stands at $0.50 compared to last year's gain of $0.65, while revenue is expected to increase by 29.7% to $15.97 billion.
What follows are some facts and figures on how Pfizer shares traded in the most recent earnings reports.
Beat revenue estimates for 4 of the past 8 quarters
Beat EPS estimates for 7 of the past 8 quarters
Beat annual EPS estimates for 3 of the past 5 years
Dollar impact? In 2008, 58% of revenue was derived from outside the United States
Pfizer shares are up 3% in 2010, and 49% since the March low
Competitors' Performance in 2010: Merck +5%, Novartis -0.7%, Amgen +4% and Biogen Idec +0.8%
Pfizer shares hit a new 52-week high of $20.36 on January 20, 2010
The company's shares are trading 0.8% above their 50-day moving average
Stock Performance By The Numbers
S&P Healthcare Sector:
Earning Estimates Source: CNBC & Thomson Reuters